Skip to main content

Advertisement

SpringerLink
Log in

Lexipafant in severe acute pancreatitis: The final word?

  • Invited Commentary
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Venkatesan T, Moulton J, Ulrich CD, et al.: Prevalence and predictors of severity as defined by Atlanta criteria in patients admitted with acute pancreatitis [abstract]. Gastroenterology 1999, 116:A1148.

    Google Scholar 

  2. Manocha AP, Sossenheimer M, Martin SP, et al.: Prevalence and predictors of severe acute pancreatitis in patients with acquired immune deficiency syndrome. Am J Gastroenterol 1999, 94:784–789.

    Article  PubMed  CAS  Google Scholar 

  3. Williams M, Simms HH: Prognostic usefulness of scoring systems in critically ill patients with severe acute pancreatitis. Crit Care Med 1999, 27:901–907.

    Article  PubMed  CAS  Google Scholar 

  4. Bradley EL: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11-13, 1992. Arch Surg 1993, 128:586–590.

    PubMed  Google Scholar 

  5. Dervenis C, Johnson CD, Bassi C, et al.: Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini Consensus Conference. Int J Pancreatol 1999, 25:195–210.

    PubMed  CAS  Google Scholar 

  6. Ulrich CD: Medical management of acute pancreatitis: strategies, reality, and potential. Curr Gastroenterol Rep 2000, 2:115–119.

    Google Scholar 

  7. Neoptolemos JP, Raraty M, Finch M, et al.: Acute pancreatitis: the substantial human and financial costs. Gut 1998, 42:886–891.

    Article  PubMed  CAS  Google Scholar 

  8. Steer ML: Early events in acute pancreatitis. Bailliere's Clin Gastroenterol 1999, 13:213–225.

    Article  CAS  Google Scholar 

  9. Brady M, Christmas S, Sutton R, et al.: Cytokines and acute pancreatitis. Bailliere's Clin Gastroenterol 1999, 13:265–289.

    Article  CAS  Google Scholar 

  10. Mayer J, Rau B, Gansuge F, et al.: Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000, 47:546–552.

    Article  PubMed  CAS  Google Scholar 

  11. Hirota M, Nozawa F, Okabe A, et al.: Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis. Pancreas 2000, 21:141–146.

    Article  PubMed  CAS  Google Scholar 

  12. Kingsnorth AN: Platelet-activating factor. Scand J Gastroenterol 1996, 219:28–31.

    CAS  Google Scholar 

  13. Johnson CD: Platelet-activating factor and platelet-activating factor receptor antagonists in acute pancreatitis. Dig Surg 1999, 16:93–101.

    Article  PubMed  CAS  Google Scholar 

  14. Curtis LD: Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Adv Exp Med Biol 1996, 416:361–363.

    PubMed  CAS  Google Scholar 

  15. Rivera JA, Werner J, Warshaw AL, et al.: Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats. Int J Pancreatol 1998, 23:101–106.

    PubMed  CAS  Google Scholar 

  16. Kingsnorth AN, Galloway SW, Formela LJ: Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human pancreatitis. Br J Surg 1995, 82:1414–1420.

    Article  PubMed  CAS  Google Scholar 

  17. McKay CJ, Curran F, Sharples C, et al.: Prospective placebocontrolled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997, 84:1239–1243.

    Article  PubMed  CAS  Google Scholar 

  18. Imrie CW, McKay CJ: The scientific basis of medical therapy of acute pancreatitis: could it work, and is there a role for lexipafant. Gastroenterol Clin North Am 1999, 28:591–599.

    Article  PubMed  CAS  Google Scholar 

  19. Johnson CD, Kingsnorth AN, Imrie CW, et al.: Double blind, randomised, placebo controlled study of a platelet-activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001, 48:62–69.

    Article  PubMed  CAS  Google Scholar 

  20. Larvin M, Ammorri B, McMahon J, et al.: A double-blind, randomised, placebo-controlled multi-centre trial to evaluate efficacy and safety of two doses of lexipafant in acute pancreatitis therapy [abstract]. Pancreatology 2001, in press.

Download references

Author information

Authors and Affiliations

  1. Pancreatic Disease Center and Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, 231 Albert B. Sabin Way, Box 670595, 45267-0595, Cincinnati, OH, USA

    Charles D. Ulrich II MD

Authors
  1. Charles D. Ulrich II MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ulrich, C.D. Lexipafant in severe acute pancreatitis: The final word?. Curr Gastroenterol Rep 3, 85–87 (2001). https://doi.org/10.1007/s11894-001-0001-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-001-0001-z

Keywords

Search

Navigation